- Home
- Companies
- brunei darussalam
- percutaneous coronary intervention
Show results for
Refine by
Percutaneous Coronary Intervention Suppliers Serving Brunei Darussalam
9 companies found
based inCarlsbad, CALIFORNIA (USA)
CeloNova BioSciences, Inc. is developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene-F nanocoating. This next-generation nanocoating is the result of years of rigorous scientific research ...
COBRA PzF NCS is the world’s first non-drug eluting, nanocoated stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT ...
based in, QUEBEC (CANADA)
Established in 2003, OpSens Medical, a division of OpSens (TSX:OPS), was founded on the belief that our innovative technologies would help to improve cardiovascular disease diagnosis and treatment. Today, our 2nd generation fiber optic OptoWire has ...
OpSens OptoWire is a modern pressure guidewire designed to assess stenoses in vessels such as coronary arteries. OptoWire is powered by Fidela™, a patented 2nd generation fiber optic sensor to measure physiologic indices including ...
based inLivermore, CALIFORNIA (USA)
Advanced Bifurcation Systems has disruptive technology for left main heart disease, stenting coronary arteries at their branch points. This platform is a paradigm shift in interventional cardiology. The ABS platform is protected by more than 36 ...
based inShanghai, CHINA
MicroPort is a global medical devices company, founded on the belief that every person has the right to high quality medical treatments and to live longer and healthier lives. All our solutions are designed to deliver on that belief. Our close ...
TARGET All Comers Trial: 1,656 Patients from 20 sites in Europe. 1:1 RCT Real World open-label, non-inferiority trial Primary endpoint: TLF @12 months. Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction ...
based inChangzhou City, CHINA
Elite Medtek was established in 2013. We are mainly engaged in the service of ODM and OEM for high-end sterile medical devices(especially for the intervention medical devices for cardiovascular technology, gastroenterology, orthopedics, and so on). ...
The inflation device, specifically utilized in Percutaneous Coronary Intervention (PCI) procedures, is engineered to apply precise pressure to balloon dilation catheters, facilitating the expansion ...
based inLeeds, UNITED KINGDOM
Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. The founding directors have significant experience in the development of medical ...
based in
Helena Laboratories is a clinical laboratory instrument and reagent manufacturer. Our clients include major medical centers, small hospitals, large reference laboratories and small private doctor's ...
Plateletworks effectively determines functional platelet count and true platelet aggregation or inhibition using traditional ADP, Collagen or Arachidonic Acid agonists. All that’s needed is an impedance cell counter and Plateletworks ...
based inBrunswick, AUSTRALIA
Avania is an integrated global, full-service CRO with specialized expertise in medical device, novel technology, and combination products. They advance products from feasibility all the way through post-approval trials in analytics, clinical trials, ...
Worldwide, heart disease is the leading cause of death. This is a primary reason why our commitment to your cardiovascular trial couldn’t be stronger. Whether your development program is geared toward treatment or prevention, you will have our ...